Management of
Spasticity in Cerebral Palsy with Neuromuscular Blockade:
The Role of Botulinum
Toxin
-
Introduction
-
Neuromuscular blockade is an
important option in management of the effects of spasticity
(Carpenter 1,2; Koman 1993, 2000; Corry 1994)
-
Spasticity
-
Definition
-
Typical patterns of extremity
spasticity (Table I)
-
Agonist-antagonist balance
-
Principles of botulinum toxin as
neuromuscular blockade
-
Historical
Perspective
-
Neuromuscular blockade
(chemodenervation)
-
Botulinum A toxin as a
therapeutic agent
-
Botulinum A toxin in cerebral
palsy
-
Anatomical
and Physiologic Considerations
-
Localization of injection
-
Neuromuscular junctions
-
Muscles and groups
-
Pharmacology (Pharmacokinetics)
-
Traditional long-lasting
neuromuscular blockade agents
-
Botulinum Toxin
-
General behavior
-
Botox® Type A Structure
(Figure 1)
-
Botox® Type A Mode
of Action (Figure 2)
-
External link: Allergan
professional information on Botox®
-
Natural
History
-
Neuromuscular blockade agents
-
Timing of chemodenervation
agents
-
Effective durations of agents
(Table II)
-
Clinical experience with
botulinum A toxin
-
Trials
-
Outcome
-
Specific evaluation of outcome
in cerebral palsy
-
Classification
-
Severity
-
Degree of spasticity
-
Function
-
Upper extremity
-
Lower extremity
-
Health-related quality of
life
-
Economic impact
-
Diagnosis
and Recognition
-
Principle of management
-
Longitudinal assessment
-
Optimal evaluation
-
Evaluation technique
-
Treatment
-
Clinical considerations
-
Clinical indications
-
Clinical contraindications
-
Absolute
-
Relative
-
Advantages
-
Disadvantages
-
Preparation
-
Drug preparation
-
Volume
-
Dosage
-
Localization technique
-
Palpation-under-stretch
-
Ultrasound
-
Electromyography
-
Diagnostic
-
Motor stimulation
-
Specific muscles / groups
-
Upper
extremity
-
Paraspinal
/ Neck
-
Lower
extremity
-
Summary
|
|